Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Edging Toward Interchangeability in Biosimilars

Executive Summary

An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.

You may also be interested in...



Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.

Sandoz Climbs 'Pyramid' To Reach Biosimilar Success

Biosimilars have turned drug development 'upside down,' where analytical confirmation outweighs clinical – a paradigm shift that must not only be embraced by the biopharmaceutical industry, but the prescribing community if US market for those products is going to be successful.

The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA

Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel